Toropainen Maija, Saarinen Leena, Wedege Elisabeth, Bolstad Karin, Michaelsen Terje E, Aase Audun, Käyhty Helena
Vaccine Immunology Laboratory, Department of Vaccines, National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland.
Infect Immun. 2005 Aug;73(8):4694-703. doi: 10.1128/IAI.73.8.4694-4703.2005.
Neisseria meningitidis, an important cause of bacterial meningitis and septicemia worldwide, is associated with high mortality and serious sequelae. Natural immunity against meningococcal disease develops with age, but the specificity and functional activity of natural antibodies associated with protection are poorly understood. We addressed this question by using a selected subset of prevaccination sera (n = 26) with convergent or discrepant serum bactericidal activity (SBA) and infant rat protective activity (IRPA) against the serogroup B meningococcal strain 44/76-SL (B:15:P1.7,16) from Icelandic teenagers. The sera were analyzed by opsonophagocytic activity (OPA) assay, immunoblotting, immunoglobulin G (IgG) quantitation against live meningococcal cells by flow cytometry, and enzyme immunosorbent assay (EIA). High levels of SBA and OPA were reflected in distinct IgG binding to major outer membrane proteins and/or lipopolysaccharide in immunoblots. However, we could not detect any specific antibody patterns on blots that could explain IRPA. Only IgM antibody to group B capsular polysaccharide (B-PS), measured by EIA, correlated positively (r = 0.76, P < 0.001) with IRPA. Normal human sera (NHS; n = 20) from healthy Finnish children of different ages (7, 14, and 24 months and 10 years) supported this finding and showed an age-related increase in IRPA that coincided with the acquisition of B-PS specific IgM antibody. The protection was independent of complement-mediated bacterial lysis, as detected by the inability of NHS to augment SBA in the presence of human or infant rat complement and the equal protective activity of NHS in rat strains with fully functional or C6-deficient complement.
脑膜炎奈瑟菌是全球细菌性脑膜炎和败血症的重要病因,与高死亡率和严重后遗症相关。针对脑膜炎球菌病的天然免疫力随年龄增长而发展,但与保护相关的天然抗体的特异性和功能活性却知之甚少。我们通过使用一组来自冰岛青少年的接种疫苗前血清(n = 26)来解决这个问题,这些血清对B群脑膜炎球菌菌株44/76-SL(B:15:P1.7,16)具有趋同或不同的血清杀菌活性(SBA)和幼鼠保护活性(IRPA)。通过调理吞噬活性(OPA)测定、免疫印迹、流式细胞术对活脑膜炎球菌细胞的免疫球蛋白G(IgG)定量以及酶免疫吸附测定(EIA)对血清进行分析。免疫印迹中高水平的SBA和OPA反映在与主要外膜蛋白和/或脂多糖的不同IgG结合上。然而,我们在印迹上未检测到任何可解释IRPA的特异性抗体模式。通过EIA测定的仅针对B群荚膜多糖(B-PS)的IgM抗体与IRPA呈正相关(r = 0.76,P < 0.001)。来自不同年龄(7、14、24个月和10岁)健康芬兰儿童的正常人血清(NHS;n = 20)支持了这一发现,并显示IRPA随年龄增长而增加,这与获得B-PS特异性IgM抗体一致。这种保护独立于补体介导的细菌裂解,这通过以下发现得以检测:在存在人或幼鼠补体的情况下,NHS无法增强SBA,以及NHS在具有完全功能或C6缺陷补体的大鼠品系中具有同等的保护活性。